Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors

Marco Danova, Sandro Barni, Lucia Del Mastro, Romano Danesi, Giovanni L. Pappagallo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Neutropenia is a frequent complication of anticancer chemotherapy (CT) often associated with life-threatening infections, hospitalization, dose reduction and/or delay in the administration of CT. Administration of recombinant granulocyte colony-stimulating factor (rG-CSF) reduces the duration and the degree of CT-neutropenia. rG-CSF that stimulates both neutropoiesis and neutrophil function, has become an integral part of supportive care during cytotoxic CT, to prevent febrile neutropenia (FN), particularly in patients with a risk of FN ≥20%. International guidelines have standardized conditions for rG-CSF administration, however, some 'gray zones' still exist around optimal timing and tailoring of this therapy. We report here the results of a research project aimed to extend the consensus on the optimal use of rG-CSF in association with CT in patient with solid tumours. We also propose a recently developed pharmacodynamic model, based on the biological effects of CT and rG -CSF on bone marrow compartments that clearly indicates within the prophylactic rather than therapeutic setting the better way of rG-CSF administration.

Original languageEnglish
Pages (from-to)1303-1313
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume11
Issue number8
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Granulocyte Colony-Stimulating Factor
Drug Therapy
Febrile Neutropenia
Neoplasms
Neutropenia
Hospitalization
Neutrophils
Bone Marrow
Guidelines
Therapeutics
Infection
Research

Keywords

  • antineoplastic agents
  • bone-marrow compartments
  • chemotherapy-induced neutropenia
  • international guidelines
  • prophylaxis
  • recombinant granulocyte colony-stimulating factor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors. / Danova, Marco; Barni, Sandro; Del Mastro, Lucia; Danesi, Romano; Pappagallo, Giovanni L.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 8, 08.2011, p. 1303-1313.

Research output: Contribution to journalArticle

Danova, Marco ; Barni, Sandro ; Del Mastro, Lucia ; Danesi, Romano ; Pappagallo, Giovanni L. / Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors. In: Expert Review of Anticancer Therapy. 2011 ; Vol. 11, No. 8. pp. 1303-1313.
@article{1342f2dc90b0483d82a46dcca2ff1f63,
title = "Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors",
abstract = "Neutropenia is a frequent complication of anticancer chemotherapy (CT) often associated with life-threatening infections, hospitalization, dose reduction and/or delay in the administration of CT. Administration of recombinant granulocyte colony-stimulating factor (rG-CSF) reduces the duration and the degree of CT-neutropenia. rG-CSF that stimulates both neutropoiesis and neutrophil function, has become an integral part of supportive care during cytotoxic CT, to prevent febrile neutropenia (FN), particularly in patients with a risk of FN ≥20{\%}. International guidelines have standardized conditions for rG-CSF administration, however, some 'gray zones' still exist around optimal timing and tailoring of this therapy. We report here the results of a research project aimed to extend the consensus on the optimal use of rG-CSF in association with CT in patient with solid tumours. We also propose a recently developed pharmacodynamic model, based on the biological effects of CT and rG -CSF on bone marrow compartments that clearly indicates within the prophylactic rather than therapeutic setting the better way of rG-CSF administration.",
keywords = "antineoplastic agents, bone-marrow compartments, chemotherapy-induced neutropenia, international guidelines, prophylaxis, recombinant granulocyte colony-stimulating factor",
author = "Marco Danova and Sandro Barni and {Del Mastro}, Lucia and Romano Danesi and Pappagallo, {Giovanni L.}",
year = "2011",
month = "8",
doi = "10.1586/era.11.72",
language = "English",
volume = "11",
pages = "1303--1313",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors

AU - Danova, Marco

AU - Barni, Sandro

AU - Del Mastro, Lucia

AU - Danesi, Romano

AU - Pappagallo, Giovanni L.

PY - 2011/8

Y1 - 2011/8

N2 - Neutropenia is a frequent complication of anticancer chemotherapy (CT) often associated with life-threatening infections, hospitalization, dose reduction and/or delay in the administration of CT. Administration of recombinant granulocyte colony-stimulating factor (rG-CSF) reduces the duration and the degree of CT-neutropenia. rG-CSF that stimulates both neutropoiesis and neutrophil function, has become an integral part of supportive care during cytotoxic CT, to prevent febrile neutropenia (FN), particularly in patients with a risk of FN ≥20%. International guidelines have standardized conditions for rG-CSF administration, however, some 'gray zones' still exist around optimal timing and tailoring of this therapy. We report here the results of a research project aimed to extend the consensus on the optimal use of rG-CSF in association with CT in patient with solid tumours. We also propose a recently developed pharmacodynamic model, based on the biological effects of CT and rG -CSF on bone marrow compartments that clearly indicates within the prophylactic rather than therapeutic setting the better way of rG-CSF administration.

AB - Neutropenia is a frequent complication of anticancer chemotherapy (CT) often associated with life-threatening infections, hospitalization, dose reduction and/or delay in the administration of CT. Administration of recombinant granulocyte colony-stimulating factor (rG-CSF) reduces the duration and the degree of CT-neutropenia. rG-CSF that stimulates both neutropoiesis and neutrophil function, has become an integral part of supportive care during cytotoxic CT, to prevent febrile neutropenia (FN), particularly in patients with a risk of FN ≥20%. International guidelines have standardized conditions for rG-CSF administration, however, some 'gray zones' still exist around optimal timing and tailoring of this therapy. We report here the results of a research project aimed to extend the consensus on the optimal use of rG-CSF in association with CT in patient with solid tumours. We also propose a recently developed pharmacodynamic model, based on the biological effects of CT and rG -CSF on bone marrow compartments that clearly indicates within the prophylactic rather than therapeutic setting the better way of rG-CSF administration.

KW - antineoplastic agents

KW - bone-marrow compartments

KW - chemotherapy-induced neutropenia

KW - international guidelines

KW - prophylaxis

KW - recombinant granulocyte colony-stimulating factor

UR - http://www.scopus.com/inward/record.url?scp=80052330744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052330744&partnerID=8YFLogxK

U2 - 10.1586/era.11.72

DO - 10.1586/era.11.72

M3 - Article

C2 - 21916584

AN - SCOPUS:80052330744

VL - 11

SP - 1303

EP - 1313

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 8

ER -